| Literature DB >> 32715129 |
Poppy Anjelisa Zaitun Hasibuan1, Urip Harahap1, Panal Sitorus2, Denny Satria2.
Abstract
Vernonia amygdalina Delile (Asteraceae) is used in traditional medicine to treat diabetes mellitus, and some research provides its activity to treat breast cancer. The aim of this study is to assess the anticancer activity of Vernonia amygdalina Delile leaves fractions on 4T1 breast cancer cells. Analysis of phytochemical compounds were carried out with LC-MS/MS. Cytotoxic activity was determined using the MTT method in the 4T1 cell line. Apoptosis, the cell cycle, and PI3K and mTOR profiles were analyzed with flow cytometry. The phytochemicals found were diterpene (ingenol-3-angelate) and some phenolics (chlorogenic acid and 4-methoxycinnamic acid), flavonoids (apigetrin, apigenin, luteolin, diosmetin, baicalin, rhoifolin, and scutellarin), and coumarines (7-hydroxycoumarine, 4-methylumbelliferone, and 4-methylumbelliferyl glucuronide). The results of the MTT assay showed that the IC50 values n-hexane fraction, ethylacetate fraction (EAF), and ethanol fractions were 1,860.54 ± 93.11, 25.04 ± 0.36, and 1,940.84 ± 96.37 μg/mL, respectively. EAF induced early and late apoptosis, inhibited cell cycle progression on the G2/M phase, and inhibited PI3K and mTOR expression. The EAF of Vernonia amygdalina Delile leaves showed anticancer activity on 4T1 breast cancer cells through induction of apoptosis, enhanced cell accumulation on G2/M phases in the cell cycle, and inhibited expression of PI3K and mTOR.Entities:
Keywords: Anticancer; Bioinformatics; Breast cancer; Cancer research; Fraction; Immunology; Leaves; Molecular biology; Toxicology; Vernonia amygdalina Delile
Year: 2020 PMID: 32715129 PMCID: PMC7371756 DOI: 10.1016/j.heliyon.2020.e04449
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Phytochemical constituent analysis of EAF with LC-MS/MS.
| No | Name | Formula | Moleculer Weight | Retention Time (min) |
|---|---|---|---|---|
| 1 | Diosmetin | C16H12O6 | 300.0633 | 0.785 |
| 2 | 4-Methylumbelliferyl glucuronide | C16H16O9 | 352.0769 | 0.955 |
| 3 | Chlorogenic acid | C16H18O9 | 354.0949 | 2.703 |
| 4 | 4-Methylumbelliferone | C10H8O3 | 176.0475 | 4.354 |
| 5 | Scutellarin | C21H18O12 | 462.0797 | 5.164 |
| 6 | Rhoifolin | C27H30O14 | 578.1634 | 5.346 |
| 7 | 7-Hydroxycoumarine | C9H6O3 | 162.0316 | 5.424 |
| 8 | Apigetrin | C21H20O10 | 432.1059 | 5.564 |
| 9 | Apigenin | C15H10O5 | 270.0521 | 5.566 |
| 10 | Baicalin | C21H18O11 | 446.0849 | 5.628 |
| 11 | Luteolin | C15H10O6 | 286.0467 | 6.888 |
| 12 | Ingenol-3-angelate | C25H34O6 | 430.2353 | 8.126 |
| 13 | 4-Methoxycinnamic acid | C10H10O3 | 178.0629 | 15.929 |
The IC50 values of Vernonia amygdalina fractions with the MTT assay of 4T1 cells (mean ± SD, three times of replication).
| Treatment | IC50 (μg/mL) |
|---|---|
| 1,860.54 ± 93.11 | |
| Ethylacetate fraction | 25.04 ± 0.36 |
| Ethanol fraction | 1,940.84 ± 96.37 |
Figure 1Representative images showing cell cycle analysis after treatment with EAF, which inhibits cell cycle progression on 4T1 cells. Percentage of the cell cycle phase of 4T1 cells treated with EAF for 24 h. (a) Control cells. (b) Cells treated with EAF at 12.5 μg/mL.
Figure 2Representative images showing apoptosis analysis using flow cytometry after treatment with EAF, which stimulates the apoptosis process on 4T1 cells. 4T1 cells were treated with EAF for 24 h and stained using Annexin-V. (a) Control cells. (b) Cells treated with EAF at 12.5 μg/mL. EAF was increased at early apoptosis and late apoptosis.
Figure 3Representative images showing the analysis of PI3K expression after treatment with EAF, which decreased the expression of PI3K protein on 4T1 cells. PI3K analysis was carried out using the flow cytometry method. 4T1 cells were treated with EAF for 24 h and stained using PI3K antibody. (a) Control cells. (b) Cells treated with EAF at 12.5 μg/mL.
Figure 4Representative images showing the analysis of mTOR expression after treatment with EAF decreased the expression of mTOR protein on 4T1 cells. The mTOR analysis was carried out using the flow cytometry method. 4T1 cells were treated with EAF for 24 h and stained using mTOR antibody. (a) Control cells. (b) Cells treated with EAF at 12.5 μg/mL.